logo image

Bevacizumab information from DrugsUpdate  

See Available Brands of Bevacizumab in India

Bevacizumab, an anti-angiogenesis, humanized anti-VEGF A inhibitor drug is prescribed to reduce the progression of malignant cells. The monoclonal antibody (biologic) is used as a combined therapy for the treatment of lungs, colorectal, renal cancer and glioblastoma.


Bevacizumab is a VEGF-receptor (Flt-1 and KDR) antagonist. These receptors are present in surface of endothelial cells. The biologic inhibits the angiogenesis by binding with VEGF ligand and thereby inhibits microvascular growth and inhibits cancer metastases.


The estimated half-life of Bevacizumab is approximately 11 – 50 days that may reach steady state after 100 days. The accumulation ratio after a dose of 10 mg/kg, every 2 weeks, is 2.8. The drug clearance differs from one patient to another depending on the body weight, gender and tumor size.

Bevacizumab Indications / Bevacizumab Uses

No information available

Bevacizumab Adverse Reactions / Bevacizumab Side Effects

Rare and serious adverse events:

Seizures, serious neurological symptoms with confusion, headache, vision changes, fatigue and fainting with high blood pressure are some of the serious adverse events of Bevacizumab. Symptoms may occur within few hours of the first dose of Bevacizumab or after intravenous injection of Bevacizumab.

Non-serious adverse events:

Other non-serious adverse events of Bevacizumab are delayed wound healing, tinnitus, fever, chills, flu-like symptoms, easy bruising, lack of coordination, back pain, taste changes, dry eyes, hair loss, hematuria or hematochezia, vaginal discharge and missed menstrual periods.


Bevacizumab is contraindicated in patients with uncontrolled hypertension, uncontrolled bleeding disorders, malena, had underwent surgery or need to undergo surgery (before or after 4 weeks), GI perforations, history of stroke or MI or CHF. Avoid activities that may increase bleeding or injury risk.

Special Precautions

No information available

Other Drug Interactions

No information available

Other Interactions

No information available


Metastatic Colorectal Cancer

As a combined therapy with 5-FU (IV), the recommended dosage of Bevacizumab is 5-10 mg/kg, every two weeks. In combination with bolus-IFL, 5 mg/kg should be administered. For FOLFOX4 combined therapy, 10 mg/kg is the recommended dosage. For Avastin-unresponsive, Oxaliplatin + Fluoropyrimidine based chemotherapy regimen, 5 mg/kg, every two weeks or 7.5 mg/kg, every three weeks should be considered.
Non-Squamous Non-Small Cell Lung Cancer
As a combined therapy with Carboplatin with Paclitaxel, administer 15 mg/kg, every 3 weeks.
Administer 10 mg/kg every 2 weeks.
Metastatic Renal Cell Carcinoma
As a combined therapy with INF-alpha, administer 10 mg/kg every 2 weeks.


No information available

List of Contraindications

Bevacizumab and Pregnancy

USFDA pregnancy category C. May be or may not be harmful to an unborn baby. Consult your doctor if you are in gestation or planning to have a baby during Bevacizumab treatment. The drug may interfere with ovulation cycle. Three or more missed periods are a prominent symptom of ovarian failure that may lead to fertility problems.

Bevacizumab and Lactation

Nursing mothers should consult the healthcare provider before Bevacizumab treatment.

Bevacizumab and Children

No information available

Bevacizumab and Geriatic

Geriatric patients are more likely to be affected by the adverse events of Bevacizumab

Bevacizumab and Other Contraindications

No information available


Store at 20-25°C.

Lab interference

Store at 20-25°C.

Bevacizumab brands in India:


© 2011-2021 DrugsUpdate.com from UPilot INC. Disclaimer | Site Map

  • Companies that own platforms will own the market
  • Trusted and recognized by all Doctors
  • Access to millions of Visitors instantly.
  • Companies that own platforms will own the market
  • Trusted and recognized by all Doctors
  • Access to millions of Visitors instantly.